



2022 Research Grants

GUIDELINES

**Applications must be received by April 4, 2022, 11:59 pm PDT
(extended deadline)**

Please send applications by e-mail to:

info@lymphoma.ca



Table of Contents

Table of Contents.....	1
About Lymphoma Canada	2
Description of Grant	2
Grant Amount and Duration.....	2
Eligibility Requirements	2
Key Dates	3
Responsibilities of the Applicant	3
Reporting	3
Acknowledgement of Lymphoma Canada.....	4
Deferral of Start Date.....	4
Grant Application and Evaluation.....	4
1. Grant Application Form	5
• Applicant Information.....	5
• Project Information	5
2. Applicant CV.....	7
3. Letter of Support.....	7
Contact Information	7



About Lymphoma Canada

Lymphoma Canada (“LC”) is a national charity focused solely on lymphoma. We raise funds to fulfil our mission – to empower the lymphoma community through education, support, advocacy and research. Background information, membership of the Board of Directors and the Scientific Advisory Board and a description of activities can be found at www.lymphoma.ca.

Description of Grant

The Lymphoma Canada Research Grants are intended to support small, well-defined research studies that have the potential to effect improvements in healthcare, health systems, and/or health outcomes as they pertain to malignant lymphoproliferative diseases.

Proposed research studies may address any of the following broad areas of research, including but not limited to:

- patient-reported outcomes;
- comparative clinical effectiveness;
- pharmaco-economics; or
- health care utilization.

Grant Amount and Duration

Grants will be offered once per year. Each grant consists of a one-time payment to a maximum of \$25,000, dependent on the nature and budget of the research study. Research studies are to be completed within the agreed upon term of the study but will not exceed 2 years of the grant start date.

The grant is valued in Canadian dollars and is taxable.

Eligibility Requirements

- Applicants can be healthcare professionals (including allied health professionals) or researchers at any stage of their career;
- must be eligible to work in Canada; and
- for the duration of the grant, be employed by a Canadian university, academic research institute, provincial cancer agency, or hospital.

Key Dates

Phase	Date
Call for proposals	January 10, 2022
Application deadline	April 4, 2022, 11:59 PM (PST) *extended
Review panel meeting	May, 2022
Notification of awards	July, 2022
Award start date	September 2022

Responsibilities of the Applicant

The applicant agrees to:

- Supervise the research and to provide the resources that are necessary for the successful completion of the research project, as appropriate.
- Use the Lymphoma Canada grant funds only for the purposes intended.
- Respect the obligations described in the Lymphoma Canada Research Grant Agreement, as well as those of the Host Institution's policies and procedures.
- Inform Lymphoma Canada and the host institution immediately of any substantive changes such as eligibility status, change of host institution or research location, etc.
- Meet all reporting requirements of Lymphoma Canada in a timely fashion.

Please note the reporting deadlines (subject to change) for the 2022-2023 grant:

Phase	Timing	Date
Interim Progress Report	6-month report	April 1, 2023 (within 30 days)
Final Report	12-month report	September 30, 2023 (within 30 days)

- Comply with the ethical and research policies outlined by the host institution and the Tri-Agency Framework: Responsible Conduct of Research.

Reporting

Progress reports are required and will be described in the award contract but should not be less than one at the end of the first year and another upon completion of the research study. The reports must include a detailed summary of the study's progress (including scientific and lay



audience summaries) and a financial statement detailing how funds were used. Annual reports are due within thirty days of the requested dates.

Acknowledgement of Lymphoma Canada

Recipients must acknowledge the support given by Lymphoma Canada in any publication or public messages made while holding a Lymphoma Canada Research Grant or work resulting from the Grant.

Deferral of Start Date

The Grant is offered with a **start date of October 1, 2022**. The start date cannot be deferred.

Grant Application and Evaluation

The Full Application is due: **April 4, 2022 (extended), 11:59 PM Pacific Time**

All components of the application must be completed and sent as a single PDF document and received by Lymphoma Canada by the deadline indicated. Incomplete or late applications will not be considered.

Applications should be mailed electronically to: info@lymphoma.ca

Please include in the subject line: Lymphoma 2022 Research Grant Applicant

Full applications will be reviewed after the submission deadline by a peer review committee. An application that does not meet the program goals, scope or guidelines will be administratively disqualified. Applications will be assigned an initial score by the primary and secondary reviewers. Only applications that fall above a scoring level determined by program staff and the committee chair will be discussed in detail for final ranking by the entire committee. Final approval of funding will be made by Lymphoma Canada's Board of Directors. Any applicant selected for funding will be notified of the funding decision in July 2021.

Applications will be evaluated by a peer-review process that will assess:

- Feasibility of the proposed work
- Potential impact on malignant lymphoproliferative diseases
- Proposed budget

The review committee will consider the following:

- Does the project rationale logically support the proposed study, and is it feasible?
- Is the proposal well-developed, with a clear aim, design, and analysis?
- Is it reasonable to expect meaningful results to support or reject the original hypothesis within 8-12 months?
- Is the budget reasonable and does not include ineligible funding?



The application consists of the following components (details provided below):

1. Grant Application Form
2. Applicant CV
3. Letter of Support

Preference for all three items (application form, CV and letter of support) to be received in one pdf package. Please keep in mind the strict page limits for each section where applicable.

1. Grant Application Form

- **Applicant Information**

The applicant must complete all fields in the space provided on the application form.

- a. **Contact information**

- b. **Academic or hospital affiliation**

- c. **Other research funds:** List other research funds and salary support currently held and applied for your research project. Include the name of the grant(s), the term of the grant(s), and the annual amount of the grant(s). There is no limit to the amount of peer-reviewed grant support that can be held in conjunction with the LC Research Grant, provided that any additional peer-reviewed funds do not overlap with the LC Research Grant funding.

- **Project Information**

The applicant must complete all fields in the space provided on the application form.

The proposal should include the following information:

- a. **Background information** (maximum 1 page)

Describe the history and nature of the research problem with reference to the existing literature. The background information should provide appropriate context of the problem in relation to theory, research, and/or practice, its scope, and the extent to which previous studies have successfully investigated the problem, noting where gaps exist that your study attempts to address.

- b. **Description of proposed research** (maximum 1 page)

Please include the following in your proposal:



- Research question(s)/objective(s)
- Specific hypothesis
- Research methodologies
- Project timeline
- Significance to lymphoproliferative malignancy: the applicant should clearly state how the proposed work addresses the problem of lymphoproliferative malignancies.

c. Detailed project budget (maximum 1 page)

The following expenditures are eligible for funding:

Salaries

- Salaries of research assistants, technicians, project coordinators and other personnel who will enhance the collaborative research productivity of the research team;
- Stipends paid to trainees (e.g., undergraduate, graduate students, postdoctoral fellows) shall be in accordance with institutional policies.

Direct research operating costs for the proposed research

- Small equipment items must be relevant to the research project and justification must be provided
- Materials and supplies
- Services
- Knowledge Translation activities which can include: publication costs relating to the funded research, other knowledge dissemination activities

The following expenditures are NOT eligible for funding received through this funding opportunity:

- Travel
- Indirect costs associated with the conduct of research (including, but are not limited to, heating, lighting, ethics review, intellectual property and commercialization activities);
- Fringe benefits for students, postdoctoral fellows and clinical research fellows
- Entertainment and hospitality costs
- Membership fees, data repository/access fees, union dues

d. Appendices (maximum 1 page): References; figures and tables



2. Applicant CV

The applicant's CV may be submitted in any format and should cover their entire career. The applicant's CV should contain the following information: previous education and professional training; previous research; list of publications and presentations (public and invited); grants.

3. Letter of Support

There is no requirement as to who this letter of support can be provided by. However, the letter should:

- Describe the applicant's personal characteristics (intellectual curiosity, leadership qualities, demonstrated interests and resourcefulness, commitment to research career, etc.)
- Provide specific details about the recognized or potential research experience (scientific training, research experience, mentoring experience, collaborations, potential to carry out independent research, etc.)

Contact Information

For questions about the Lymphoma Canada Research Grant, please contact:

Kaitlyn Beyfuss-Laski

National Scientific Director

905.858.5967

1.866.658.5556

kaitlyn@lymphoma.ca